Evista in Chile: prescription, pharmacy and pricing
Evista (Raloxifene) is available in Chile under the regulatory framework of ISP (Instituto de Salud Pública de Chile, Public Health Institute). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Evista 60mg.
- Regulator
- ISP (Instituto de Salud Pública de Chile, Public Health Institute)
- Currency
- CLP
- Active ingredients
- Raloxifene
- Available dosages
- 60mg
Prescription status in Chile
Chile classifies medicines into venta directa (OTC) and receta médica (prescription); receta retenida applies to controlled substances and remains in the pharmacy. The public health system FONASA and private ISAPRE plans cover prescription costs at varying levels, often with a Bonificación copay. Evista contains the active ingredient Raloxifene, in the Hormones and Birth Control class, and its classification in Chile follows the standard rules of ISP (Instituto de Salud Pública de Chile, Public Health Institute).
Pharmacy dispensing
Chilean pharmacies are dominated by three large chains — Cruz Verde, Salcobrand and Ahumada — plus a network of independent farmacias populares run by municipalities. Pharmacist counselling is typically brief at chain dispensing and more thorough at populares. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Evista at the available strengths (60mg).
Online and tele-prescribing access
Online medicine sale in Chile is permitted through ISP-registered pharmacies; the three major chains offer mature online platforms with tracked deliveries. Online prescription handling requires uploading a valid receta and pharmacist verification before dispensing. Buying Evista from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Raloxifene.
When Evista is prescribed
Evista is approved for prevention and treatment of postmenopausal osteoporosis and for reduction of invasive breast cancer risk in postmenopausal women at increased risk.
Pricing and availability in CLP
Retail pricing in Chile depends on the strength (60mg), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Evista in Chile? ▾
Chile classifies medicines into venta directa (OTC) and receta médica (prescription); receta retenida applies to controlled substances and remains in the pharmacy. The public health system FONASA and private ISAPRE plans cover prescription costs at varying levels, often with a Bonificación copay. In practice, Evista follows the status of its active ingredient Raloxifene in the regulatory system of ISP (Instituto de Salud Pública de Chile, Public Health Institute).
Is generic Evista available in Chile? ▾
Authorised generics of Raloxifene are typically available in Chile at a lower cost than branded Evista, with bioequivalence required by ISP (Instituto de Salud Pública de Chile, Public Health Institute). Substitution is handled by the pharmacist under local equivalence rules.
How much does Evista cost in CLP? ▾
Prices in CLP vary by pharmacy and by strength (60mg). Authorised generics of Raloxifene are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in Chile.
Evista in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- AustriaBASG (Federal Office for Safety in Health Care)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.